Close

Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Go back to Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Viking Therapeutics (VKTX) Misses Q2 EPS by 2c

August 1, 2019 4:44 PM EDT

Viking Therapeutics (NASDAQ: VKTX) reported Q2 EPS of ($0.11), $0.02 worse than the analyst estimate of ($0.09).

"The second quarter was an especially active period at Viking, highlighted by our presentation of additional VK2809 clinical data, as well as continued progress toward our planned Phase 2b study in biopsy-confirmed NASH," stated... More